Erlotinib for Progressive Brain and Leptomeningeal Metastases From HER2-positive Breast Cancer After Treatment Failure With Trastuzumab and Lapatinib: Experience and Review of Literature

Clin Breast Cancer. 2018 Oct;18(5):e759-e765. doi: 10.1016/j.clbc.2018.07.022. Epub 2018 Aug 4.

Authors

Guanghui Ji¹, Chenyang Zhang², Shan Guan¹, Xiangying Yao³

Affiliations

¹ Department of Traditional Chinese Medicine, Navy General Hospital, Beijing, China.
² Geriatric Digestive System Department, Navy General Hospital, Beijing, China.
³ Department of Traditional Chinese Medicine, Navy General Hospital, Beijing, China. Electronic address: yaoxiangying@163.com.

PMID: 30177482
DOI: 10.1016/j.clbc.2018.07.022

No abstract available

Keywords: Brain metastasis; Erlotinib; Meningeal metastasis; Next-generation sequencing; Targeted therapy.

Publication types

Case Reports
Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / genetics
Brain Neoplasms / diagnosis
Brain Neoplasms / drug therapy*
Brain Neoplasms / genetics
Brain Neoplasms / secondary
Breast Neoplasms / genetics
Breast Neoplasms / pathology*
Erlotinib Hydrochloride / therapeutic use*
Female
Humans
Meningeal Neoplasms / diagnosis
Meningeal Neoplasms / drug therapy*
Meningeal Neoplasms / genetics
Meningeal Neoplasms / secondary
Middle Aged
Molecular Targeted Therapy
Mutation
Protein Kinase Inhibitors / therapeutic use*
Receptor, ErbB-2 / genetics*
Treatment Outcome

Substances

Antineoplastic Agents
Biomarkers, Tumor
Protein Kinase Inhibitors
Erlotinib Hydrochloride
ERBB2 protein, human
Receptor, ErbB-2